1991年同济医科大学药学院药学本科毕业留校任教至今，期间于1997年获药学硕士学位，2007年获药学博士学位。

1.猪苓多糖与rIL-2结合物长循环脂质体及抗瘤活性研究. 省科技攻关计划. 2003.07—2004.12，第一负责人。

2.新型补铁剂当归多糖铁的研制. 省科技攻关计划. 2005.07—2006.12，第一负责人。

3.当归多糖铁协同补血的血细胞调控分子生物学机理研究.省自然科学基金. 2007.01—2008.12，第一负责人。

4.当归多糖铁协同补血的血细胞调控分子生物学机理研究.省中医药中西医结合科研课题.2007.01—2008.12，第一负责人。

5.药学实验教材建设与改革.中华医学会医学教育科研课题. 2007.12-2008.12，第一负责人。

6.当归多糖铁口服液的研制与开发.市科技攻关计划.2008.01-2009.12，第一负责人。

7.湖北道地植物多糖及其铁复合物开放铁释放通道调节铁代谢的作用研究.省自然基金重点项目.2008.10-2011.09，第一负责人。

8.当归多糖抑制hepcidin表达的分子机制研究. 国家自然科学基金，2010.01-2010.12，第一负责人。

9.当归多糖特异性肝靶向的分子机理研究. 国家自然科学基金，2011.01-2013.12，第一负责人。

10.当归多糖作为肝靶向给药系统载体的可行性研究. 华中科技大学自然重点项目，2010.10-2012.09，第一负责人。

11.香菇多糖药用研究. 横向课题, 2011.06-2013.06，第一负责人。

12.当归多糖作为铁调素抑制剂参与机体铁代谢的分子机制研究. 国家自然科学基金，2013.01-2016.12，第一负责人。

13.香菇多糖非免疫途径抗肿瘤作用的分子机制研究. 武汉市科技攻关, 2013.01-2014.12, 第一负责人。

14.香菇多糖抗肿瘤构效关系及诱导肿瘤细胞凋亡的分子机制研究. 国家自然科学基金, 2014.01-2017.12, 第二负责人。

15．药用植物多糖的绿色提取工艺、结构鉴定及新剂型的关键技术研发. 湖北省科技支撑计划项目2014BKB088, 2014.1-2015.12，第一负责人。

16. 当归多糖调节机体糖脂代谢紊乱的分子机制研究. 武汉市科技计划，2016.08-2018.08，第一负责人。

17. 中药复方多糖提取工艺、降糖降脂功效及新剂型的关键技术研究. 湖北省技术创新专项重大项目 。2017.01-2018.12，第一负责人。

18. 生血宁片通过调节EPO表达改善肾性贫血的作用及分子机制研究.横向课题.2018.03-2019.09，第一负责人。

19. 中药复方多糖提取工艺及降糖降脂功效研究. 横向课题. 2018.06-2020.06，第一负责人。

20. 天然多糖体内检测方法的建立和药代动力学机制研究. 省自然基金重点项目. 500万.第一负责人。

21. Dectin-1介导的香菇多糖体内吸收代谢机制研究.中国医疗手牵手工程. 100万. 2020.1-2013.12，第一负责人。

1. Synthesis, purification, and anticancer effect of magnetic Fe3O4-loaded poly (lactic-co-glycolic) nanoparticles of the natural drug tetrandrine. Journal of Microencapsulation, (2019) 1-15

2. Angelica sinensis polysaccharide nanoparticles as a targeted drug delivery system for enhanced therapy of liver cancer. Carbohydrate Polymers, 2019,219:143-154

3. Oral administration of Angelica sinensis polysaccharide protects against pancreatic islets failure in type 2 diabetic mice: Pancreatic β-cell apoptosis inhibition. Journal of Functional Foods 54 (2019): 361-370

4. Correction of anemia in chronic kidney disease with Angelica sinensis polysaccharide via restoring EPO production and improving iron availability. Front Pharmacol. 2018; 9: 803.

5. A sensitive and rapid radiolabelling method for the in vivo pharmacokinetic study of lentinan. Food Funct., 2018, 9, 3114-3125

6. Functional polysaccharide Lentinan suppresses human breast cancer growth via inducing autophagy and caspase-7-mediated apoptosis. Journal of Functional Foods. June 2018, 75–85

7. Angelica sinensis polysaccharide protects against acetaminophen-induced acute liver injury and cell death by suppressing oxidative stress and hepatic apoptosis in vivo and in vitro. International Journal of Biological Macromolecules .2018 May;111:1133-1139

8. Dendrobium officinale polysaccharide attenuates type 2 diabetes mellitus via the regulation of PI3K/Akt-mediated glycogen synthesis and glucose metabolism. Journal of Functional Foods. January 2018, Pages 261-271

9. Pharmacokinetics, biodistribution and receptor mediated endocytosis of a natural Angelica sinensis polysaccharide. Artificial Cells, Nanomedicine, and Biotechnology. 2017: 1-10.

10. Investigation of the transport and absorption of Angelica sinensis polysaccharide through gastrointestinal tract both in vitro and in vivo. Drug Delivery. 2017 Nov;24(1):1360-1371.

11. Acidic Polysaccharide from Angelica sinensis Reverses Anemia of Chronic Disease Involving the Suppression of Inflammatory Hepcidin and NF-κB Activation, Oxidative Medicine and Cellular Longevit, Volume 2017,13 pages.

12. Silkworm feces extract improves iron deficiency anemia via suppressing hepcidin expression and promoting iron-regulatory proteins expression. RSC Adv.2017,7,50378–50388

13. A polysaccharide from Lentinus edodes inhibits human colon cancer cell proliferation and suppresses tumor growth in athymic nude mice，oncotarget. 2017 Jan 3; 8(1): 610–623

14. Protective effects of Angelica sinensis polysaccharide against hyperglycemia and liver injury in multiple low-dose streptozotocininduced type 2 diabetic BALB/c mice, Food &Function. 2016,7, 4889-4897

15. Chronic administration of Angelica sinensis polysaccharide effectively improves fatty liver and glucose homeostasis in high-fat diet-fed mice, Sci. Rep. 2016,6:26229

16. Polysaccharide from Lentinus edodes combined with oxaliplatin possesses the synergy and attenuation effect in hepatocellular carcinoma, cancer letters. 2016,377:117-125

17. Structural characterization and in vitro antitumor activity of an acidic polysaccharide from Angelica sinensis (Oliv.) Diels. Carbohydrate Polymers. 2016,147:401-408

18. The effects of polysaccharides from the root of Angelica sinensis on tumor growth and iron metabolism in H22-bearing mice. Food & Function. 2016,7:1033-1039

19. Angelica sinensis polysaccharide attenuates concanavalin A-induced liver injury in mice. International Immunopharmacology. 2016,31:140-148

20. Induction of apoptosis in S180 tumour bearing mice by polysaccharide from Lentinus edodes via mitochondria apoptotic pathway. Journal of functional foods. 2015,15:151-159.

21. Angelica sinensis polysaccharide regulates glucose and lipid metabolism disorder in prediabetic and streptozotocin-induced diabetic mice through the elevation of glycogen levels and reduction of inflammatory factors. Food & Function. 2015,6:902-909.

22. The action of JAK, SMAD and ERK signal pathways on hepcidin suppression by polysaccharides from Angelica sinensis in rats with iron deficiency anemia. Food & Function,2014,5:1381-1388.

23. Structural differences and conformational characterization of five bioactive polysaccharides from Lentinus Edodes. Food Research International, 2014, 62:223-232.

24. Alkali-Soluble Polysaccharide, Isolated from Lentinus edodes, Induces Apoptosis and G2/M Cell Cycle Arrest in H22 Cells Through Microtubule Depolymerization. Phytotherapy Research,2014, 12:1837-1845

25. Structure and inducing tumor cell apoptosis activity of polysaccharide isolated from Lentinus edodes. Journal of agricultural and food chemistry, 2013,61(41):9849-9858.

26. Polysaccharide isolated from angelica sinensis inhibits hepcidin expression in rats with iron deficiency anemia. Journal of Medical Food, 2012,15 (10):923–929.

27. Study to establish the role of JAK2 and SMAD1/5/8 pathways in the inhibition of hepcidin by polysaccharides from Angelica sinensis. Journal of Ethnopharmacology, 2012, 144(10):433-440

28. Comparison of two kinds of magnetic nanoparticles in vivo and in vitro. J Huazhong Univ Sci Technol,2012,32(3):444-450

29. Inhibitory effect of polysaccharides isolated from Angelica sinensis on hepcidin expression. Journal of Ethnopharmacology, 2011, 134(3): 944- 948

30. Structure，Chain comformation and antitumor activity of a novel polysaccharide from Lentinus edodes. Fitoterapia, 2010, 81(8): 1163-1170

31. Studies on the Molecular Weight and Proposed Structure of the Angelica sinensis Polysaccharide-iron Complex[J]. Chinese Journal of Chemistry, 2008, 26(6):1-7

32. Effect of Angelica sinensis Polysaccharide-iron Complex on Iron Deficiency Anemia Rats. Chinese Journal of Integrative Medicine，2007,13(4):297-300

33. Effects of angelica sinensis polysaccharide-iron complex on hemolytic anemia and bone marrow injury in mice. Journal of Chinese Pharmaceutical Sciences，2008，（17）:197-202

34. Preparation and Identification of Angelica sinensis Polysaccharide-iron Complex. Chemical Research in Chinese Universities,2005,21(6): 668-672

35.当归多糖铁治疗缺铁性贫血大鼠实验研究,中国新药与临床杂志,2007, 26(6):413-416

36.当归多糖铁理化性质的初步研究.中国中药杂志,2006,18(2):71-73

37.当归多糖铁胃内漂浮缓释胶囊的制备及质量控制.中国医院药学杂志, 2007，27(7):951-953

38.当归多糖铁小鼠口服的急性毒性研究. 中国医院药学杂志,2009,29(4):291-292.

39.人hepcidin真核表达载体的构建及稳定转染细胞系的建立. 华中科技大学学报(医学版)，2010,39（4）：524-527

40.当归多糖铁大鼠体内药动学参数与给药剂量的关系. 中国医院药学杂志，2010，30（3）：183-185

41.当归多糖铁胃内滞留缓释片的制备及其犬体内药动学. 中国医院药学杂志，2011，31（5）：365-369

42.当归多糖铁复合物在大鼠体内2种不同吸收途径的研究. 中国医院药学杂志，2011，31（7）：531-535

43.当归多糖铁胃内滞留缓释片在犬体内的药物动力学研究. 药物分析杂质，2011，31（4）：629-632